Therapeutic Advances in Hematology

Papers
(The H4-Index of Therapeutic Advances in Hematology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Prognostic impact of IL7R mutations on acute myeloid leukemia38
Brain iron content and cognitive function in patients with β-thalassemia32
BEST study: one-year descriptive follow-up of bevacizumab treatment in hereditary haemorrhagic telangiectasia post-BABH interventional study29
Real-world study of use patterns and clinical outcomes for patients with myelodysplastic syndrome initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents28
Effective engraftment via granulocyte transfusion in pre-engraftment febrile neutropenia following allogeneic hematopoietic stem cell transplantation: granulocyte transfusion as bridge therapy21
Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine19
Role of abatacept in the prevention of graft-versus-host disease: current perspectives16
A comparison of the effect of three different comorbidity indices on overall survival in patients with chronic myeloid leukemia16
Macrofocal multiple myeloma in the era of novel agents in China16
Treatment of multiple myeloma: What is the impact on T-cell function?14
Efficacy and safety of Busulfan–Fludarabine versus Busulfan–Cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplant in hematologic malignancy patients: a meta-analysis o14
Efficacy and safety of immunosuppressive therapy in connective tissue disease-related immune thrombocytopenia: a systematic review and meta-analysis13
Successful maintenance of a sustained molecular response in CML patients receiving low-dose tyrosine kinase inhibitors13
0.14239406585693